DVD 1: Plenary Session I DVD 3: Chronic Lymphocytic Leukemia, Molecular Abnormalities and Gene Expression Changes in AML. Are we Ready for a Prognostic Debate: Fludarabine vs. Chlorambucil. Is the Battle Molecular Prioritization? What is the impact on Over? Personalized AML Therapy? Torsten Haferlach, MD Chlorambucil – Still Not Bad CLL: How Much Progress? What is the Future? Michael J. Keating, MB, BS Fludarabine the Winner Close to the Cure in CML IMIDs Combinations in CLL
How Can We Exploit the CLL Microenvironment? Jan A. Burger, MD, PhD DVD 2: Chronic Lymphocytic Leukemia,
FCR Now Frontline Therapy DVD 4: Acute Lymphoblastic Leukemia Treatment of Adolescents and Young Adults – Do the Biologic Factors add any Significance over Pediatric versus Adult Regimens? the Clinical and Classical Prognostic Factors? Monoclonal Antibodies in ALL Therapy – Any Role of Old and New Monoclonal Antibodies, Alone Progress? and in Combinations Targeted Therapies in Ph-positive ALL: Which is the Novel Inhibitors of B-Cell Signaling Best TKI? What is the Role of Chemotherapy? Transplant in CLL--When, How, and What to Expect Minimal Residual Disease: What Does it Mean? Is it now a Therapeutic Target? What do the Genetics Tell us? Can we Translate the Findings into Therapies? Novel Drugs and Strategies in ALL: Breakthroughs on the Horizon? Treatment in CLL - the Age Old Question Allogeneic SCT for ALL in CR1: Grounds for Optimism? DVD 5: Myeloproliferative Disorders DVD 7: Myelodysplastic Syndromes Pathophysiology of MPDs and Role of JAK2 Mutations SNPs and other Molecular Changes in MDS – Ready for Primetime? JAK2 Inhibitors – Are they the Solution? Novel Pathophysiologic Pathways in MDS Role of IMIDs in Myelofibrosis IMIDs in MDS -- What Have We Learned So Far? Interferon Alfa in PV and ET Prognostic Factors and Risk Models in MDS Prognostic Factors and Models in PV, ET, and MF Debate: Role of Allogeneic SCT in MDS Critical to Cure MDS Theo de Witte, MD, PhD DVD 6: Myelodysplastic Syndromes Part I, Plenary Session II Minimal Benefit in MDS Progress with Epigenetic Therapy in MDS – Are We Stuck? Novel Agents and Strategies in MDS Plenary Session II Growth Factors (EPO, GCSF, TPO) in the Modern Era Eva S. Hel ström-Lindberg, MD, PhD Cure of Myeloma, A Personal Odyssey Any Progress in MPDs? Ayalew Tefferi, MD DVD 8: Acute Myeloid Leukemia Part I State of the Art Therapy of Younger AML – Lesson Debate: Iron Chelation Therapy in MDS – Is it from Large Randomized Clinical Trials Useful? Absolutely Necessary to Improve Outcome Debate: Treatment of Older AML Intensive Chemotherapy is the Best Approach No Data to Prove its Benefit Low Intensity Therapy is the Way of the Future DVD 8: Acute Myeloid Leukemia Part I (…cont) DVD 10: Multiple Myeloma (…cont) State of the Art Therapy of APL – The Lo Coco Adverse Cytogenetic and Biologic Factors in Approach Myeloma Role of Allogeneic SCT in CR1 IMIDs, Proteosome Inhibitors, Combos. What is Best? FLT3 Mutations and FLT3 Inhibitors – Last Nail in Coffin or Resuscitation Waldenstrom’s Macroglobulinemia – Where does Therapy Stand? New Treatments and Strategies in AML DVD 11: Lymphoma
DVD 9: Acute Myeloid Leukemia Part II Any Progress Since R-CHOP? Marrow Microenvironment and Targeted Therapies Is Bendamustine + Rituxan the Best Treatment for Indolent Lymphoma? Micro RNA and Molecular Profiling in AML – Is it Relevant? What is Optimal Therapy in Early Large Cell Lymphoma? WBC Transfusions, Irradiated, Unirradiated? Indolent Lymphomas – Observe, BR, RCHOP, Others? DVD 10: Multiple Myeloma Hodgkin’s Disease – Cured but not Conquered Pathophysiology of Myeloma – Lessons into the Clinic SCT Improves Outcome in Myeloma Bart Barlogie, MD Novel Agents and Combinations in Myeloma Antonio Palumbo, MD DVD 12: Chronic Myeloid Leukemia DVD 13: Special Topics Debate: What is the Ideal Frontline CML Therapy? State of the Art New Antifungals Dimitrios Kontoyiannis, MD Imatinib Allogeneic SCT in Leukemias – Overview 2nd Generation TKIs Multipotent Mesenchymal Stromal Cells (MSC) – Evolving Role in Cancer and Leukemia Therapy Salvage Strategies Post Imatinib Failure – What to do Now? Interesting Statistics in Leukemia Debate: Optimal Monitoring in CML? Intensive Monitoring is Essential Too Much for Too Little Debate: Role of Allogeneic SCT As Salvage Post Imatinib Failure As Salvage Post 2 TKI Failures Do We Have Better Prognostic Tools in CML? Can We Improve on Frontline CML Therapy?
An Elephant’s Knowledge: Chronic Post Surgical Pain It was a busy Monday morning in theatres and I was already feeling anxious. My consultant was running late and Mrs Johnson, who was listed for a mastectomy was in tears. She said that her sister had had a mastectomy 8 years ago and that she had been in pain ever since; she was desperately worried the same thing would happen t